Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Johan Schultz"'
Autor:
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 498-502 (2021)
Abstract ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C,
Externí odkaz:
https://doaj.org/article/0aa8be017263486cb8f895e3be923506
Autor:
Walter Z. Wang, Konstantin Shilo, Joseph M. Amann, Alyssa Shulman, Mohammad Hojjat-Farsangi, Håkan Mellstedt, Johan Schultz, Carlo M. Croce, David P. Carbone
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-9 (2021)
Abstract Small cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emergin
Externí odkaz:
https://doaj.org/article/8e3d803832bd442687414f1eec0b50ef
Autor:
Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
Publikováno v:
Pharmaceutics, Vol 15, Iss 4, p 1148 (2023)
The ROR1 receptor tyrosine kinase is expressed in embryonic tissues but is absent in normal adult tissues. ROR1 is of importance in oncogenesis and is overexpressed in several cancers, such as NSCLC. In this study, we evaluated ROR1 expression in NSC
Externí odkaz:
https://doaj.org/article/1287c54575b8479d88d0bd97b869a154
Autor:
Amineh Ghaderi, Wen Zhong, Mohammad Ali Okhovat, Johanna Aschan, Ann Svensson, Birgitta Sander, Johan Schultz, Thomas Olin, Anders Österborg, Mohammad Hojjat-Farsangi, Håkan Mellstedt
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2238 (2022)
The receptor tyrosine kinase orphan receptor 1 (ROR1) is absent in most normal adult tissues but overexpressed in various malignancies and is of importance for tumor cell survival, proliferation, and metastasis. In this study, we evaluated the apopto
Externí odkaz:
https://doaj.org/article/1ddf361c3275497c927bb40fd3abd27c
Autor:
Nina M. S. Gustafsson, Katarina Färnegårdh, Nadilly Bonagas, Anna Huguet Ninou, Petra Groth, Elisee Wiita, Mattias Jönsson, Kenth Hallberg, Jemina Lehto, Rosa Pennisi, Jessica Martinsson, Carina Norström, Jessica Hollers, Johan Schultz, Martin Andersson, Natalia Markova, Petra Marttila, Baek Kim, Martin Norin, Thomas Olin, Thomas Helleday
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
Targeting the glycolytic PFKFB3 enzyme is being studied as a therapeutic strategy against cancer. Here the authors identify PFKFB3 as being involved in homologous recombination (HR) repair of DNA double strand breaks (DSBs) and present a PFKFB3 inhib
Externí odkaz:
https://doaj.org/article/a5be37faa19d4d1fbbb9c428f096c524
Autor:
Amineh Ghaderi, Amir Hossein Daneshmanesh, Ali Moshfegh, Parviz Kokhaei, Jan Vågberg, Johan Schultz, Thomas Olin, Sara Harrysson, Karin E Smedby, Elias Drakos, Georgios Z. Rassidakis, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
Publikováno v:
Biomedicines, Vol 8, Iss 6, p 170 (2020)
The receptor tyrosine kinase ROR1 is absent in most normal adult tissues, but overexpressed in several malignancies. In this study, we explored clinical and functional inhibitory aspects of ROR1 in diffuse large B-cell lymphoma (DLBCL). ROR1 expressi
Externí odkaz:
https://doaj.org/article/d36a9e454ef446bc87fdc28c52d68ddd
Autor:
Amir Hossein Daneshmanesh, Mohammad Hojjat-Farsangi, Amineh Ghaderi, Ali Moshfegh, Lotta Hansson, Johan Schultz, Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Thomas Olin, Anders Österborg, Håkan Mellstedt
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198038 (2018)
There is a great unmet medical need in pancreatic carcinoma (PC) for novel drugs with other mechanisms of action than existing. PC cells express the onco-fetal RTK ROR1, absent on most normal post-partem cells. ROR1 is involved in proliferation, surv
Externí odkaz:
https://doaj.org/article/8743e38417724615841dfe2b2b650da9
Publikováno v:
Ericsson Technology Review. 2021:2-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44835de14ae2be814f7663c5e70b4f5b
https://doi.org/10.23919/etr.2021.9904657
https://doi.org/10.23919/etr.2021.9904657
Autor:
Thomas Olin, Ann Mari Svensson, Håkan Mellstedt, Layung Sekar Sih Wikanthi, Johan Schultz, Mohammad Ali Okhovat, Anders Österborg, Mohammad Hojjat-Farsangi, Amineh Ghaderi, Marzia Palma
Publikováno v:
eJHaem. 2:498-502
ROR1 - a receptor tyrosine kinase - is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a8be5074b8d32192431f558e23ad56
https://doi.org/10.1002/jha2.232
https://doi.org/10.1002/jha2.232
Autor:
Mohammad, Hojjat-Farsangi, Ali, Moshfegh, Johan, Schultz, Martin, Norin, Thomas, Olin, Anders, Österborg, Håkan, Mellstedt
Publikováno v:
Handbook of experimental pharmacology. 269
Receptor tyrosine kinases (RTKs) are frequently dysregulated in malignancies and important for the malignant characteristics of tumor cells. RTKs are attractive structures for drug targeting of cancer. The RTK ROR1 is of significance during embryogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::41213b9484f21d6c978b466a72981061
https://pubmed.ncbi.nlm.nih.gov/34490515
https://pubmed.ncbi.nlm.nih.gov/34490515